Keyword: talazoparib

With ASCO ending, it's time to round up our favorite quotes from the weekend. Read on to see the most colorful things pharma executives had to say.

Despite a field that features four entrants and a wealth of data supporting their use, some doctors still aren't on board with PARP inhibitors.

The FDA approved Pfizer's PARP inhibitor, Talzenna, in breast cancer, but its ability to grab share depends on expanding the market.

The FDA has granted priority review for Pfizer's PARP inhibitor talazoparib, but the drug could struggle to meet high expectations given stiff competition.

Closely watched maker of cancer drugs Tesaro is up for sale, the WSJ reports, with its new PARP inhibitor Zejula at the heart of a potential deal.

Call it an early spring surprise for Tesaro. Its closely watched cancer med niraparib—now dubbed Zejula—won an FDA nod Monday, months before its scheduled decision date.

Merck & Co. wants Medivation, too. Not content to let another Big Pharma snap up the cancer-focused biotech unchallenged, Merck has joined the fight for a prize valued at more than $10 billion.